| 1 |
2022 |
3-T magnetic resonance-guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. |
3T-MR-HIFU, BM, QoL, SREs |
| 2 |
2022 |
Analyzing Differences in Perception between Oncologists and Patients to Adapt Pharmacological Treatment for Breakthrough Cancer Pain: Observational ADAPTATE Study. |
TF |
| 3 |
2022 |
Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment. |
WoS |
| 4 |
2022 |
Clinical Practice Guidelines in the Management of Breakthrough Cancer Pain: A Systematic Review using the Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument. |
CPGs, ICC |
| 5 |
2022 |
Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. |
QoL |
| 6 |
2022 |
Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. |
OR |
| 7 |
2021 |
Characterizing Breakthrough Cancer Pain Using Ecological Momentary Assessment with a Smartphone App: Feasibility and Clinical Findings. |
apps, EMA |
| 8 |
2021 |
CT-Guided Coeliac Plexus Neurolysis in Patients with Intra-Abdominal Malignancy: A Retrospective Evaluation of 52 Palliative In-Patients. |
CAP, CPB, CPN |
| 9 |
2021 |
Cultural adaptation and psychometric validation of the Portuguese breakthrough pain assessment tool with cancer patients. |
BAT, BAT, re |
| 10 |
2021 |
Current management of cancer pain in Italy: Expert opinion paper. |
--- |
| 11 |
2021 |
Effect of a theory-driven educational intervention on the level of knowledge, attitudes, and assessment practices regarding breakthrough cancer pain (BTCP) management among medical nurses in Hong Kong. |
--- |
| 12 |
2021 |
Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study. |
QoL |
| 13 |
2021 |
Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. |
IOPS-MS, MCA, NP-BTcP |
| 14 |
2021 |
Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. |
BGP, IOPS-MS, NRS |
| 15 |
2021 |
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study. |
BPI, IQ-BTP |
| 16 |
2021 |
The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. |
OME |
| 17 |
2021 |
Understanding the Chameleonic Breakthrough Cancer Pain. |
--- |
| 18 |
2021 |
What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. |
--- |
| 19 |
2020 |
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. |
--- |
| 20 |
2020 |
Breakthrough cancer pain in 2020. |
--- |
| 21 |
2020 |
Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription. |
ROOs |
| 22 |
2020 |
Breakthrough cancer pain: review and calls to action to improve its management. |
--- |
| 23 |
2020 |
Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study. |
--- |
| 24 |
2020 |
Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. |
ESAS, HRQoL, PSQI |
| 25 |
2020 |
Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication. |
IRF |
| 26 |
2020 |
Interference with daily functioning by breakthrough pain in patients with cancer. |
BPI, IDF, NRS, QoL |
| 27 |
2020 |
Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer. |
FPNS |
| 28 |
2020 |
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. |
FBT, INFS, OTFC |
| 29 |
2020 |
[Status and Rationality of Opioid Use in Lung Cancer Patients: A Single Center Retrospective Study]. |
DDC |
| 30 |
2019 |
Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. |
OME |
| 31 |
2019 |
Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. |
--- |
| 32 |
2019 |
Current management of breakthrough cancer pain according to physicians from pain units in Spain. |
--- |
| 33 |
2019 |
Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial. |
QoL |
| 34 |
2019 |
Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. |
FPNS, VAS |
| 35 |
2019 |
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. |
AEs, MCS, PCS, PI, SF-12v2, SFTs |
| 36 |
2019 |
Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. |
--- |
| 37 |
2019 |
Is pain part of a systemic syndrome in head and neck cancer? |
HNC |
| 38 |
2019 |
Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy. |
--- |
| 39 |
2019 |
Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain. |
PC |
| 40 |
2019 |
Usability, Acceptability, and Usefulness of an mHealth App for Diagnosing and Monitoring Patients With Breakthrough Cancer Pain. |
--- |
| 41 |
2019 |
Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. |
IQR, MED |
| 42 |
2018 |
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). |
--- |
| 43 |
2018 |
Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. |
--- |
| 44 |
2018 |
Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain. |
PPGs |
| 45 |
2018 |
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. |
OM, TIRF |
| 46 |
2018 |
Breakthrough cancer pain: The importance of the right treatment at the right time. |
HCPs |
| 47 |
2018 |
Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study. |
--- |
| 48 |
2018 |
Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review. |
--- |
| 49 |
2018 |
Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm. |
ECS-CP |
| 50 |
2018 |
The use of fentanyl in pain management in head and neck cancer patients: a narrative review. |
TTS |
| 51 |
2018 |
Treating breakthrough pain in oncology. |
--- |
| 52 |
2017 |
Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. |
ROO |
| 53 |
2017 |
Breakthrough cancer pain and rational drug use. |
--- |
| 54 |
2017 |
Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model. |
Cx, GFAP, GJ, p-Cx43 |
| 55 |
2017 |
Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. |
OFFs, QALYs |
| 56 |
2017 |
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. |
FBT, NRS |
| 57 |
2017 |
High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. |
QoL |
| 58 |
2017 |
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. |
CPG, SEOM |
| 59 |
2016 |
Breakthrough Cancer Pain: Ten Commandments. |
--- |
| 60 |
2016 |
Breakthrough cancer pain: twenty-five years of study. |
--- |
| 61 |
2016 |
Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. |
--- |
| 62 |
2016 |
Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain. |
FPNS |
| 63 |
2016 |
Erratum to: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. |
--- |
| 64 |
2016 |
Fentanyl citrate sublingual formulation (Vellofent) for quick BTcP hindering. |
--- |
| 65 |
2016 |
Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management ofBreakthrough Cancer Pain: A Comparative Study. |
FPNS, OM |
| 66 |
2016 |
Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. |
ATC, FSS, TFP |
| 67 |
2016 |
From "Breakthrough" to "Episodic" Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. |
--- |
| 68 |
2016 |
Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. |
AEs |
| 69 |
2016 |
Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey. |
CI, OR |
| 70 |
2016 |
Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. |
--- |
| 71 |
2016 |
What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. |
--- |
| 72 |
2015 |
A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting. |
BCP |
| 73 |
2015 |
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. |
PI |
| 74 |
2015 |
Accuracy of a Diagnostic Algorithm to Diagnose Breakthrough Cancer Pain as Compared With Clinical Assessment. |
--- |
| 75 |
2015 |
An Observational Research Study to Evaluate the Impact of Breakthrough Cancer Pain on the Daily Lives and Functional Status of Patients. |
--- |
| 76 |
2015 |
Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. |
IOPS |
| 77 |
2015 |
Comparing the effectiveness of intranasal fentanyl spray with oral transmucosal fentanyl citrate in breakthrough pain. |
INFS, OTFC |
| 78 |
2015 |
Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). |
--- |
| 79 |
2015 |
Effective Dose Titration of Fentanyl Sublingual Spray in Patients With Breakthrough Cancer Pain. |
AE |
| 80 |
2015 |
Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. |
FBTs, OM |
| 81 |
2015 |
Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. |
FBT, PGIC |
| 82 |
2015 |
Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. |
TIRF |
| 83 |
2014 |
Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. |
BP, ROO |
| 84 |
2014 |
Breakthrough cancer pain: the current situation. |
--- |
| 85 |
2014 |
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. |
--- |
| 86 |
2014 |
Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. |
OM, OM, SLF, SLF, VAS |
| 87 |
2014 |
Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose. |
AEs, ATC, rs |
| 88 |
2014 |
Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain. |
AE, SE, TSQM |
| 89 |
2014 |
Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. |
--- |
| 90 |
2014 |
Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain. |
NRS, OTFC |
| 91 |
2013 |
A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. |
INFS, PID |
| 92 |
2013 |
Breakthrough pain in patients with abdominal cancer pain. |
--- |
| 93 |
2013 |
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain. |
--- |
| 94 |
2013 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. |
AEs, BTncP, BTP, sublingual fentanyl ODT, VAS |
| 95 |
2013 |
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. |
FBT, ODT, OTFC |
| 96 |
2013 |
European Oncology Nursing Society breakthrough cancer pain guidelines. |
--- |
| 97 |
2013 |
Fentanyl for the treatment of tumor-related breakthrough pain. |
RCTs |
| 98 |
2013 |
How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey. |
--- |
| 99 |
2013 |
Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit. |
--- |
| 100 |
2013 |
Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. |
AEs, AUClast, tmax |
A Search Service for Abbreviation / Long Form
